Source: CureToday articles
Antihistamines may be associated with survival improvement in patients with metastatic urothelial carcinoma receiving Tecentriq.
Recent Content
- NLA 2025: Understanding the Impact of Omega-3 Fatty Acids on LDL Cholesterol
- Harnessing the Tumor Microenvironment for Enhanced Cancer Treatment
- NLA 2025: Exploring the Evidence Behind Omega-3 Fatty Acids for Cardiovascular Risk
- From Resistance to Response: The Microbiome’s Role in Optimizing Cancer Therapy
- NLA 2025: GLP-1 Therapies May Impact Cardiovascular and Renal Health Independent of Weight Loss
- Day 2: Top Takeaways From ASCO25
- NLA 2025: Novel Therapeutic Approaches Show Promise for Targeted Reduction of Lp(a) in Patients With ASCVD
- ESR1, PIK3CA, and Beyond: Precision Therapy Advances in HR+ Breast Cancer
- Updated ASCO-NCODA MIP Standards Emphasize Health Equity, Patient-Centered Care, and Integrated Workflows in Oral Oncolytic Management
- A simple genomic score to predict progression of multiple myeloma